Search

Your search keyword '"Contino, Silvia"' showing total 19 results
Start Over Author "Contino, Silvia"
19 results on '"Contino, Silvia"'

1. The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors

Author

Incorvaia, Lorena, Bazan Russo, Tancredi Didier, Gristina, Valerio, Perez, Alessandro, Brando, Chiara, Mujacic, Clarissa, Di Giovanni, Emilia, Bono, Marco, Contino, Silvia, Ferrante Bannera, Carla, Vitale, Maria Concetta, Gottardo, Andrea, Peri, Marta, Galvano, Antonio, Fanale, Daniele, Badalamenti, Giuseppe, Russo, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

3. Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”

Author

Gottardo, Andrea, Gristina, Valerio, Perez, Alessandro, Di Giovanni, Emilia, Contino, Silvia, Barraco, Nadia, Bono, Marco, Iannì, Giuliana, Randazzo, Ugo, Bazan Russo, Tancredi Didier, Iacono, Federica, Incorvaia, Lorena, Badalamenti, Giuseppe, Russo, Antonio, Galvano, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

4. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints

Author

Fanale, Daniele, Corsini, Lidia Rita, Bono, Marco, Randazzo, Ugo, Barraco, Nadia, Brando, Chiara, Cancelliere, Daniela, Contino, Silvia, Giurintano, Ambra, Magrin, Luigi, Pedone, Erika, Perez, Alessandro, Piraino, Paola, Pivetti, Alessia, Giovanni, Emilia Di, Russo, Tancredi Didier Bazan, Prestifilippo, Ornella, Gennusa, Vincenzo, Pantuso, Gianni, Russo, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

6. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?

Author

Incorvaia, Lorena, Perez, Alessandro, Marchetti, Claudia, Brando, Chiara, Gristina, Valerio, Cancelliere, Daniela, Pivetti, Alessia, Contino, Silvia, Di Giovanni, Emilia, Barraco, Nadia, Bono, Marco, Giurintano, Ambra, Bazan Russo, Tancredi Didier, Gottardo, Andrea, Cutaia, Sofia, Pedone, Erika, Peri, Marta, Corsini, Lidia Rita, Fanale, Daniele, Galvano, Antonio, Scambia, Giovanni, Badalamenti, Giuseppe, Russo, Antonio, and Bazan, Viviana

Published
2023
Full Text
View/download PDF

9. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: looking for new tumor biological fingerprints

Author

Fanale, Daniele, primary, Corsini, Lidia Rita, additional, Bono, Marco, additional, Randazzo, Ugo, additional, Barraco, Nadia, additional, Brando, Chiara, additional, Cancelliere, Daniela, additional, Contino, Silvia, additional, Giurintano, Ambra, additional, Magrin, Luigi, additional, Pedone, Erika, additional, Perez, Alessandro, additional, Piraino, Paola, additional, Pivetti, Alessia, additional, Giovanni, Emilia Di, additional, Russo, Tancredi Didier Bazan, additional, Prestifilippo, Ornella, additional, Gennusa, Vincenzo, additional, Pantuso, Gianni, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2023
Full Text
View/download PDF

10. Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors

Author

Bazan Russo, Tancredi Didier, Mujacic, Clarissa, Di Giovanni, Emilia, Vitale, Maria Concetta, Ferrante Bannera, Carla, Randazzo, Ugo, Contino, Silvia, Bono, Marco, Gristina, Valerio, Galvano, Antonio, Perez, Alessandro, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Abstract

The most remarkable finding in synthetic lethality (SL) is the hypersensitivity to PARP inhibitors (PARPis) of the tumors harboring defects in genes involved in homologous repair (HR) such as BRCA1/2. Despite initial responsiveness to PARPi, the penetrance of the synthetic lethal interactions between BRCA1/2genes and PARPi is incomplete. Thus, a significant proportion of HR-defective tumors experience intrinsic or acquired resistance, representing a key challenge of clinical research. An expanded concept of SL is opening new ways and includes novel forms of genetic interactions, investigating not only traditional SL of pairs genes but also SL between biological pathways that regulate the same essential survival cell function. In this context, recent research showed that HR and theta-mediated end-joining (TMEJ) pathways exhibit SL. DNA polymerase theta (Polθ) is encoded by the POLQgene and is a key component of the TMEJ, an essential backup pathway, intrinsically mutagenic, to repair resected double-strand breaks (DSBs) when the non-homologous end joining (NHEJ) and HR are impaired. Polθ is broadly expressed in normal tissues, overexpressed in several cancers, and typically associated with poor outcomes and shorter relapse-free survival. Notably, HR-deficient tumor cells present the characteristic mutational signatures of the error-prone TMEJ pathway. According to this observation, the loss of HR proteins, such as BRCA1 or BRCA2, contributes to increasing the TMEJ-specific genomic profile, suggesting synthetic lethal interactions between loss of the POLQand HR genes, and resulting in the emerging interest for Polθ as a potential therapeutic target in BRCA1/2-associated tumors.

Published
2024
Full Text
View/download PDF

11. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Dimino, Alessandra, primary, Brando, Chiara, additional, Algeri, Laura, additional, Gristina, Valerio, additional, Pedone, Erika, additional, Peri, Marta, additional, Perez, Alessandro, additional, De Luca, Ida, additional, Sciacchitano, Roberta, additional, Magrin, Luigi, additional, Bazan Russo, Tancredi Didier, additional, Bono, Marco, additional, Barraco, Nadia, additional, Contino, Silvia, additional, La Mantia, Maria, additional, Galvano, Antonio, additional, Badalamenti, Giuseppe, additional, Russo, Antonio, additional, Bazan, Viviana, additional, and Incorvaia, Lorena, additional

Published
2022
Full Text
View/download PDF

13. Risk Factors for Anaplastic Thyroid Carcinoma: A Case Series From a Tertiary Referral Center for Thyroid Surgery and Literature Analysis

Author

Graceffa, Giuseppa, primary, Salamone, Giuseppe, additional, Contino, Silvia, additional, Saputo, Federica, additional, Corigliano, Alessandro, additional, Melfa, Giuseppina, additional, Proclamà, Maria Pia, additional, Richiusa, Pierina, additional, Mazzola, Sergio, additional, Tutino, Roberta, additional, Orlando, Giuseppina, additional, and Scerrino, Gregorio, additional

Published
2022
Full Text
View/download PDF

15. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.

Author

Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
BIOMARKERS, GENETICS, GENETIC mutation, IMMUNE system, GASTROINTESTINAL tumors, GENE expression, TREATMENT effectiveness, PHENOTYPES, IMMUNOTHERAPY, SARCOMA
Abstract

Simple Summary: The effect of genetic alteration on the prognosis of patients affected by GIST has been extensively demonstrated. Unfortunately, not all GISTs could benefit from targeted therapies, underlining the need to deeply understand other predictive mechanisms. The link between immune checkpoints (especially PD-L1 expression), the tumor microenvironment, and the clinical behavior of GIST with different driver mutations is under investigation and represents an intriguing research field that could lead to improved prognostication in GIST. Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.

Author

Incorvaia, Lorena, Brando, Chiara, Perez, Alessandro, Bono, Marco, Cancelliere, Daniela, Pivetti, Alessia, Barraco, Nadia, Contino, Silvia, Raso, Chiara Annamaria, Carreca, Anna Paola, Gristina, Valerio, Galvano, Antonio, Bazan Russo, Tancredi Didier, Castellana, Luisa, Insalaco, Lavinia, Fanale, Daniele, Marchetti, Claudia, Bazan, Viviana, Russo, Antonio, and Carreca, Ignazio

Published
2023
Full Text
View/download PDF

18. Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer.

Author

Gottardo, Andrea, Russo, Tancredi Didier Bazan, Perez, Alessandro, Bono, Marco, Di Giovanni, Emilia, Di Marco, Enrico, Siino, Rita, Bannera, Carla Ferrante, Mujacic, Clarissa, Vitale, Maria Concetta, Contino, Silvia, Iannì, Giuliana, Busuito, Giulia, Iacono, Federica, Incorvaia, Lorena, Badalamenti, Giuseppe, Galvano, Antonio, Russo, Antonio, Bazan, Viviana, and Gristina, Valerio

Abstract

The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non‐invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour‐related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi‐marker, multi‐analyte and multi‐source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Alessandra Dimino, Chiara Brando, Laura Algeri, Valerio Gristina, Erika Pedone, Marta Peri, Alessandro Perez, Ida De Luca, Roberta Sciacchitano, Luigi Magrin, Tancredi Didier Bazan Russo, Marco Bono, Nadia Barraco, Silvia Contino, Maria La Mantia, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia, Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
Cancer Research, immune system, Oncology, target therapy, tumor microenvironment, immunotherapy, immune checkpoints, sarcomas, GIST
Abstract

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results